Moderna seeks FDA nod to use COVID-19 vaccine in younger kids
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) shares are trading higher in the pre-market Thursday after the company said it submitted a request for emergency use authorization (EUA) to the U.S. regulators for use of its COVID-19 vaccine in children aged six months â six years.

Moderna (MRNA) expects the EUA submission to complete next week.
Cambridge, Massachusetts-based biotech said that similar requests are currently underway overseas to seek authorization for two doses of mRNA-1273 vaccine at 25 Î¼g as the primary series.
Regulatory submissions are based on data from Phase 2/3 KidCOVE study for mRNA-1273, and the company said that the studies are ongoing to evaluate booster shots of the vaccine for all pediatric groups. 
Early this week, rival vaccine makers, Pfizer (PFE) and BioNTech (BNTX) sought FDAâs EUA for a 10-Âµg booster dose of their vaccine for children aged five through 11 years.